Clinical Trial

Prostate Cancer Awareness and Initiative for Screening in the European Union

Study acronym: PRAISE-U
Enrolling by Invitation
View on ClinicalTrials.gov →
Record status
This record was last updated August 15, 2025 (before its estimated April 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
PRAISE-U was initiated on the 1st of April 2023 and is set to last for three years. This collaborative effort involves 25 institutions across 12 countries, all driven by a shared objective: to rationalize prostate cancer screening in Europe and enhance patient outcomes. PRAISE-U advocates for EU member states to offer exceptional clinical standards, incorporating cutting-edge personalized approaches to enable timely detection of prostate cancer in individuals who can benefit from early treatment. To assess the functionality, feasibility, and long-term viability of a risk-based algorithm, the consortium will collaborate with pilot sites in Spain, Poland, Ireland, and Lithuania.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-05-16.
Status change: Not Yet Recruiting → Enrolling by Invitation 2025-08-12
Trial Details
NCT Number NCT06424275
Lead Sponsor European Association of Urology Research Foundation
Collaborators: Erasmus Medical Center, European Randomised Study of Screening for Prostate Cancer, Region MidtJylland Denmark, Institute of Health Information and Statistics of the Czech Republic, UMC Utrecht, EUROPEAN CANCER ORGANISATION, Dolnośląskie Centrum Onkologii, Pulmonologii i Hematologii, Narodowy Instytut Zdrowia Publicznego, Conselleria de Sanidade de Galicia, Althaia Xarxa Assistencial Universitària de Manresa, Vastra Gotaland Region, Region Skane, National Cancer Institute (NCI), University Ghent, Health Service Executive, Ireland, Estonian Urological Association, University College Dublin, WONCA Europe, Movember Foundation, International Agency for Research on Cancer, European Society of Urogenital Radiology, Europa UOMO, Czech Urological Society
Conditions Prostate Cancer
Enrollment 20,000 participants
Start Date 2024-06-01
Primary Completion 2026-04-01 (estimated)
Study Completion 2026-04-01 (estimated)
Updated on ClinicalTrials.gov 2025-08-15